Light Sciences announce approval for Japanese licensor

Share this article:

Seattle-based Light Sciences reported that Meiji Seika, the licensor of its lead compound, LS11 (Laserphyrin in Japan), received a recommendation for approval by Pharmaceutical Affairs and Food Sanitation Council of the Ministry of Health, Labor and Welfare in Japan. The approval will be granted for the photodynamic treatment of early endobronchial carcinoma.

The Japanese regulatory decision in the world's second largest healthcare market comes as Light Sciences has successfully completed a phase I/II study of its lead combination product, Litx, in patients with advanced stage solid cancers. One of the key components of the Litx System is the light activated LS11 drug.

"The Japanese recommendation for approval of our lead drug coincides with the initiation of our Phase II oncology program internationally," stated Dr. Albert Luderer, Light Sciences' president and chief executive. "This regulatory milestone sets a positive tone for the next phase of Litx evaluation."

Light Sciences licensed LS11 from Nippon Petrochemicals and Meiji Seika Kaisha in early 2000, and has exclusive rights to develop, make and commercialize the compound for use in photodynamic therapy in multiple therapeutic applications worldwide, outside of Japan.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.